nach oben

Current Hepatology Reports

Erschienen in:

20.10.2021 | Hepatitis C (H Vargas and S Flamm, Section Editors)

Addressing Hepatitis B in the Context of Hepatitis C

verfasst von: Lauren Myers, Arnab Mitra, Joseph Ahn

Erschienen in: Current Hepatology Reports | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

There are worldwide efforts focused on targeting the screening and treatment of viral hepatitis B and C. This review highlights liver and treatment-related impacts of hepatitis B and C dual infection.

Recent Findings

It is important to identify the subset of individuals who may have been coinfected with both hepatitis B and C who are at increased risk for liver fibrosis, hepatocellular carcinoma as well as clinically significant hepatitis B reactivation when hepatitis C is treated. Those with hepatitis B surface antigen positivity are at greatest risk for hepatitis B reactivation. Treatment with newer direct-acting antivirals (DAA) has been associated with earlier onset hepatitis B reactivation and more severe hepatitis than prior interferon-based hepatitis C treatments.

Summary

Several practice guidelines have been published that recommend close monitoring with hepatitis B serologies and laboratory screening during hepatitis C treatment as well as preemptive antiviral treatment of hepatitis B in the highest risk groups to optimize clinical outcomes.

Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23(4):512–20. https://doi.org/10.1111/j.1440-1746.2008.05384.x.CrossRefPubMed

Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int. 2009;3(4):517–25. https://doi.org/10.1007/s12072-009-9147-9.CrossRefPubMedPubMedCentral

Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58(2):538–45. https://doi.org/10.1002/hep.26400.CrossRefPubMed

Kruse RL, Kramer JR, Tyson GL, Duan Z, Chen L, El-Serag HB, et al. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014;60(6):1871–8. https://doi.org/10.1002/hep.27337.CrossRefPubMed

Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010;51(3):759–66. https://doi.org/10.1002/hep.23461.CrossRefPubMed

Pol S, Haour G, Fontaine H, Dorival C, Petrov-Sanchez V, Bourliere M, et al. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017;46(11–12):1054–60. https://doi.org/10.1111/apt.14352.CrossRefPubMed

Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512–21. https://doi.org/10.1136/gutjnl-2018-316601.CrossRefPubMed

•• Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. https://doi.org/10.1002/hep.29800. (This paper highlights practice guidelines for hepatitis B from American Association for the Study of Liver Diseases.)CrossRefPubMed

Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol. 2014;20(40):14559–67. https://doi.org/10.3748/wjg.v20.i40.14559.CrossRefPubMedPubMedCentral

10.

Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43(1):100–7. https://doi.org/10.1002/hep.20944.CrossRefPubMed

11.

Cornberg M, Wong VW-S, Locarnini S, Brunetto M, Janssen HLA, Chan HL-Y. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66(2):398–411. https://doi.org/10.1016/j.jhep.2016.08.009.CrossRefPubMed

12.

Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8. https://doi.org/10.1016/s0140-6736(16)30579-7.CrossRefPubMedPubMedCentral

13.

Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28(1):27–33. https://doi.org/10.1016/s0168-8278(98)80198-0.CrossRefPubMed

14.

Butt AA, Yan P, Aslam S, Abou-Samra AB, Sherman KE, Shaikh OS. Liver fibrosis progression and mortality in Hepatitis B- and C-coinfected persons treated with directly acting antiviral agents: results from ERCHIVES. Clin Infect Dis. 2019. https://doi.org/10.1093/cid/ciz1097.CrossRefPubMedPubMedCentral

15.

Liu C-J, Tseng T-C, Yang W-T, Su T-H, Yang H-C, Liu C-H, et al. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. J Gastroenterol Hepatol. 2019;34(2):410–7. https://doi.org/10.1111/jgh.14455.CrossRefPubMed

16.

•• HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2020. https://www.hcvguidelines.org. Accessed 6/1/2020 2020. (This are the American Association for the Study of Liver Diseases and Infectious Diseases Society of America guidelines for treating hepatitis C.)

17.

•• EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. https://doi.org/10.1016/j.jhep.2017.03.021. (This paper highlights practice guidelines for treatment of hepatitis B from the European Association for the Study of the Liver.)

18.

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. https://doi.org/10.1007/s12072-015-9675-4.CrossRefPubMed

19.

Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS. Prevalence of hepatitis B reactivation among Chinese individuals with chronic hepatitis C treated with pan-oral direct-acting antivirals. Gastroenterol Res. 2018;11(2):124–9. https://doi.org/10.14740/gr971w.CrossRef

20.

Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. Peginterferon Alfa-2a Plus Ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136(2):496-504.e3. https://doi.org/10.1053/j.gastro.2008.10.049.CrossRefPubMed

21.

Tamori A, Abiru S, Enomoto H, Kioka K, Korenaga M, Tani J, et al. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy. J Viral Hepat. 2018;25(5):608–11. https://doi.org/10.1111/jvh.12840.CrossRefPubMed

22.

Ogawa E, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV. Liver Int. 2018;38(1):76–83. https://doi.org/10.1111/liv.13496.CrossRefPubMed

23.

Doi A, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R, et al. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: analysis of a Japanese prospective cohort. Hepatol Res. 2017;47(13):1438–44. https://doi.org/10.1111/hepr.12919.CrossRefPubMed

24.

Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir Ther. 2016;21(7):605–9. https://doi.org/10.3851/imp3066.CrossRefPubMed

25.

Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, et al. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat. 2017;24(12):1098–106. https://doi.org/10.1111/jvh.12737.CrossRefPubMed

26.

• Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017;166(11):792–8. https://doi.org/10.7326/m17-0377. (This document highlights cases that prompted the Food and Drug Administration black box warnings on hepatitis C DAA treatments.)

27.

Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132–6. https://doi.org/10.1016/j.cgh.2016.06.023.CrossRefPubMed

28.

Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66(1):27–36. https://doi.org/10.1002/hep.29135.CrossRefPubMed

29.

• Mücke MM, Backus LI, Mücke VT, Coppola N, Preda CM, Yeh M-L, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(3):172–80. https://doi.org/10.1016/S2468-1253(18)30002-5. (This article is a meta-analysis of HBV reactivation in setting of DAA HCV treatment.)CrossRefPubMed

30.

Osman HA, Ghweil AA, Sabry AM, Mahdy RE, Khodeary A. Management of patients with hepatitis B virus reactivation post-DAA treatment of chronic hepatitis C virus infection in HCV-HBV coinfected patients with pretreatment HBeAg seroconversion and early degree of hepatic Fibrosis. Infect Drug Resist. 2019;12:3067–73. https://doi.org/10.2147/IDR.S215974.CrossRefPubMedPubMedCentral

31.

• Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66(1):13–26. https://doi.org/10.1002/hep.29109. (This article is a meta-analysis of HBV reactivation in setting of DAA HCV treatment.)CrossRefPubMed

32.

Sastre L, Ruiz P, Costa J, Forns X. Severe hepatitis B reactivation during direct-acting antiviral treatment in “the absence” of hepatitis B surface antigen. Int J Infect Dis. 2019;79:47–9. https://doi.org/10.1016/j.ijid.2018.11.014.CrossRefPubMed

33.

Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164. https://doi.org/10.1186/s13256-015-0630-8.CrossRefPubMedPubMedCentral

34.

Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 2016;9(4):252–6. https://doi.org/10.1007/s12328-016-0657-4.CrossRefPubMed

35.

Yeh M-L, Huang C-F, Huang C-I, Holmes JA, Hsieh M-H, Tsai Y-S, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol. 2020. https://doi.org/10.1016/j.jhep.2020.01.027.CrossRefPubMed

36.

•• EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology. 2018;69(2):461–511. https://doi.org/10.1016/j.jhep.2018.03.026. (This paper highlights practice guidelines for treatment of hepatitis C from the European Association for the Study of the Liver.)

37.

•• Kanda T, Lau GKK, Wei L, Moriyama M, Yu M-L, Chuang W-L, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hep Intl. 2019;13(6):649–61. https://doi.org/10.1007/s12072-019-09988-7. (This document highlights updated recommendations from Asian Pacific Association of the Study of the Liver around hepatitis B reactivation during DAA treatment of Hepatitis C.)CrossRef

38.

•• Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10(5):702–26. https://doi.org/10.1007/s12072-016-9717-6. (This paper highlights practice guidelines for treatment of hepatitis C from the Asian Pacific Association of the Study of the Liver.)CrossRefPubMed

39.

Liu C-J, Chuang W-L, Sheen IS, Wang H-Y, Chen C-Y, Tseng K-C, et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology. 2018;154(4):989–97. https://doi.org/10.1053/j.gastro.2017.11.011.CrossRefPubMed

40.

Butt AA, Yan P, Aslam S, Sherman KE, Siraj D, Safdar N, et al. Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: results from ERCHIVES. Int J Infect Dis. 2020;92:184–8. https://doi.org/10.1016/j.ijid.2020.01.025.CrossRefPubMed

41.

Combating hepatitis B and C to reach elimination by 2030.: World Health Organization [WHO]; 2016.

42.

Hepatitis C Virus Infection in Adolescents and Adults: Screening. U.S. Preventive Services Task Force. 2020. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening. Accessed 9/14/20 2020.

43.

Wiktor SZ. Where next for hepatitis B and C surveillance? J Viral Hepat. 2015;22(7):571–3. https://doi.org/10.1111/jvh.12400.CrossRefPubMed

44.

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207. https://doi.org/10.1016/s2214-109x(17)30375-3.CrossRefPubMedPubMedCentral

45.

Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology. 2017;152(6):1578–87. https://doi.org/10.1053/j.gastro.2017.03.018.CrossRefPubMed

46.

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50. https://doi.org/10.1002/hep.29913.CrossRefPubMed

47.

Servoss JC, Friedman LS. Serologic and molecular diagnosis of hepatitis B virus. Clin Liver Dis. 2004;8(2):267–81. https://doi.org/10.1016/j.cld.2004.02.001.CrossRefPubMed

48.

Interpretation of Hepatitis B Serologic Test Results. Centers for Disease Control and Prevention. Updated 10/2019. https://www.cdc.gov/hepatitis/hbv/pdfs/SerologicChartv8.pdf. Accessed 8/13/2020 2020.

49.

Interpretation of Results of Tests for Hepatitis C Virus (HCV) Infection and Further Actions. Centers for Disease Control and Prevention. Updated 8/7/2020. https://www.cdc.gov/hepatitis/HCV/PDFs/hcv_graph.pdf. Accessed 8/13/20 2020.

Titel: Addressing Hepatitis B in the Context of Hepatitis C
verfasst von: Lauren Myers
Arnab Mitra
Joseph Ahn
Publikationsdatum: 20.10.2021
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 4/2021
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-021-00578-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Addressing Hepatitis B in the Context of Hepatitis C

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Emerging Biomarkers for HBV Cure: HBsAg and Beyond

Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease

Diagnostic Testing for SARS-CoV-2 Infection

Real-World Safety and Effectiveness of Oral Nucleos(t)ide Analogs in the Treatment of Chronic Hepatitis B Virus Infection

Management of Hepatitis B in Persons Who Inject Drugs (PWID)

Viral Hepatitis B—Management in Children

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin